In contrast, in a retrospective study by Chen et al of 366 patients with squamous cell carcinoma of

the mid-thoracic esophagus, local recurrence rates were significantly lower with adjuvant radiation therapy compared to chemotherapy or observation (20%, 32%, 43%, respectively) (33). Postoperative chemoradiation versus surgery alone The INT-0116 trial published by MacDonald et al prospectively randomized 556 patients with gastroesophageal junction (GEJ) (approximately 20%) Inhibitors,research,lifescience,medical or gastric adenocarcinoma patients, Stage IB-IV (AJCC 3th Edition) who had undergone curative resection with negative margins to receive no further therapy or to postoperative chemoradiation (one cycle of 5-FU and leucovorin followed by Inhibitors,research,lifescience,medical concurrent radiation to 45 Gy with the same agents, followed by two additional cycles of 5-FU and leucovorin) (34). Patients were required to have sufficient caloric intake of 1500 Kcal per day. Because of the complicated nature of RT field design for gastric carcinomas, RT quality assurance was conducted prior to radiation delivery, and both minor and major deviations were detected in 35% of cases and corrected. Three-year overall Erlotinib clinical survival improved with addition of chemoradiation from 41% to 50% as well as median survival from 27 http://www.selleckchem.com/products/AZD2281(Olaparib).html months to 36 months with chemoradiation.(HR

Inhibitors,research,lifescience,medical 1.35 for death with surgery alone group compared to adjuvant CRT, 95% CI 1.09-1.66, p=0.005). Local recurrence rates were also reduced from 29% with surgery alone to 19% with

the addition of CRT. This trial provides the rationale for the use of postoperative Inhibitors,research,lifescience,medical CRT for GEJ adenocarcinomas. In patients with GEJ adenocarcinomas, CRT is appropriate to improve survival and local control. Table 4 Prospective trials of postoperative chemoradiation Of note, in the 6th Edition of the AJCC manual, GEJ carcinomas could be included in esophageal or gastric Inhibitors,research,lifescience,medical stage groupings and could produce different stage groupings depending on either the use of the esophageal or gastric stage groupings. GEJ carcinoma also previously included the locally advanced stages of T4 Nx or Tx N3 (Stage IV as stated above) when grouped with gastric cancer (35). In the AJCC 7th Edition, the GEJ carcinomas are now staged with esophageal, rather than gastric cancers, and include cancer within the first 5 cm of the stomach AV-951 that extends into the GEJ or distal thoracic esophagus (2),(36). In addition, Stage IV disease currently only refers to M1 staging and does not include any locally advanced disease. A phase II trial of postoperative CRT for poor prognosis esophagus and GEJ adenocarcinoma (86%) and squamous cell carcinomas (14%) investigated postoperative 5-FU, cisplatin and RT to 50.4-59.4 Gy in 50 patients with node positive or T3/T4 tumors (5). 4-year freedom from recurrence was 50%, distant metastatic control 56%, and locoregional control 86%, with a median survival of 53 months, comparing favorably with a historical median survival of 28 months in prior trials (37).